

*C3
C9*
C10

R_{6'} is hydrogen, halogen, trifluoromethyl, alkyl and alkoxy;

R₆-R₉ are the same or different and selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, halo-alkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or adjacent groups

R₆-R₉ form ring structures which may be further substituted;

R₁₀ is hydrogen or forms an alkylene chain together with R₃; and

R₁₁ and R₁₂ are the same or different and selected from the group consisting of hydrogen, halogen or alkyl.

24. A method for improving inhibition of gastric acid secretion comprising administering to a patient in need thereof the oral pharmaceutical formulation according to claim 19.

25. A method for improving the treatment of gastrointestinal disorders associated with excess acid secretion comprising administering to a patient in need thereof the oral pharmaceutical formulation according to claim 19.

REMARKS

This Supplemental Amendment is necessary to delete claim 22, an improper multiple dependent claim, that was introduced by the previous Amendment. As such, the amendments and new claims are necessary to place the claims in conformance with U.S. patent law practice and to ensure that the claims cover specific embodiments of the claimed invention. Applicants submit that no new matter has been added by any of the amendments.

CONCLUSION

Claims 1-11, 15, 16, 18-21 and 23-25 are pending upon entry of this Supplemental Amendment. All of the pending claims are patentable for the reasons set forth in the preceding Amendment, mailed October 1999. Accordingly, the claims are in condition for allowance, which action is earnestly solicited.

Any fees in connection with this response should be charged to Deposit Account No. 23-1703.

Dated: October 29, 1999

Respectfully submitted,



John M. Genova
Reg. No. 32,224
Attorney for Applicants

White and Case LLP
Patent Department
1155 Avenue of the Americas
New York, NY 10036-2787
(212) 819-8200